BioCatalystWatch
XNCRWorkspace / XNCR / OverviewCompany library
Price
Market cap
Next catalystExpected Q1 2027XmAb657 — healthy-participant SAD and planned autoimmune-patient MAD cohorts · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

XmAb657

CD19 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

XmAb942

TL1A

PreINDP1P2P3FilingApproved
XmAb819

ENPP3 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

XmAb412

TL1A × IL-23 p19

PreINDP1P2P3FilingApproved
Upcoming / outlook

XmAb541

CLDN6 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

XmAb541

CLDN6 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

XmAb657

CD19 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

XmAb541

CLDN6 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

XmAb541

CLDN6 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

XmAb819

ENPP3 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

XmAb412

TL1A × IL-23 p19

PreINDP1P2P3FilingApproved
Upcoming / outlook

XmAb942

TL1A

PreINDP1P2P3FilingApproved

Other pipelines

XmAb819

ENPP3 × CD3

PreINDP1P2P3FilingApproved
XmAb412

TL1A × IL-23 p19

PreINDP1P2P3FilingApproved
XmAb541

CLDN6 × CD3

PreINDP1P2P3FilingApproved
XmAb541

CLDN6 / CD3

PreINDP1P2P3FilingApproved
XmAb541

CLDN6 / CD3

PreINDP1P2P3FilingApproved
XmAb541

CLDN6 / CD3

PreINDP1P2P3FilingApproved
XmAb819

ENPP3 × CD3

PreINDP1P2FilingApproved
Upcoming / outlook

tidutamab

SSTR2 × CD3

Partner / License out

FcγRIIb × CD19

PreINDP1P2P3FilingApproved

FcγRIIb × CD19

PreINDP1P2P3FilingApproved

C5

Approved

PreINDP1P2P3FilingApproved

C5

Approved

PreINDP1P2P3FilingApproved

STEAP1 × CD3

PreINDP1P2P3FilingApproved

Approved / commercial

CD19

PreINDP1P2P3FilingApproved

C5

PreINDP1P2P3FilingApproved

History / paused

XmAb942

TL1A

CD20 × CD3

PreINDP1P2P3FilingApproved

PD-1 × ICOS

PreINDP1P2P3FilingApproved

PD-1 × ICOS

PreINDP1P2P3FilingApproved

PD-1 × ICOS

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

XNCR PR & News

PR & News

XNCR SEC archive